Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trimethoprim + sulfamethoxazole + rifampicin
- Development stage
- Unknown
- Lead developer
- University Hospital
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This combination antibiotic regimen consists of trimethoprim-sulfamethoxazole (TMP-SMX) and rifampicin. It was specifically evaluated by researchers at the University Hospital, Geneva, for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections. The regimen typically involves oral or intravenous administration of TMP-SMX (160/800 mg) three times daily combined with rifampicin (600 mg) once daily. The mechanism of action is synergistic: TMP-SMX inhibits two consecutive steps in the bacterial biosynthesis of essential nucleic acids and proteins (folate synthesis pathway), while rifampicin inhibits bacterial DNA-dependent RNA polymerase, thereby suppressing RNA synthesis. This combination was studied in a Phase 4 trial (NCT00711854) to provide a cost-effective oral alternative to linezolid or vancomycin for MRSA.
- Other names
- TMP-SMX + rifampicinco-trimoxazole + rifampicin
02
Targets
DHFR (Dihydrofolate reductase)RNAP (Bacterial dna-dependent RNA polymerase)DHPS (Dihydropteroate synthase)
Beyond the preview
Go deeper on trimethoprim + sulfamethoxazole + rifampicin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trimethoprim + sulfamethoxazole + rifampicin.